⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IOBT News
IO Biotech, Inc. Common Stock
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
globenewswire.com
JNJ
BNTX
GMAB
IMUX
INO
PDSB
AZN
GSK
MRK
BIIB
EXEL
REGN
CUE
IOBT
RAPT
PRE
Elevara Medicines Appoints Biotech Veteran as CEO
globenewswire.com
IOBT
Delisting of Securities from The Nasdaq Stock Market
globenewswire.com
MLGO
EPWK
IVP
SYNX
TWIN
FAT
CASI
TRX
ITRM
IOBT
Form 8-K
sec.gov
IOBT
Bavarian Nordic A/S – Notice Convening Annual General Meeting
globenewswire.com
JNJ
UCB
GSK
SNY
VICR
IOBT
FLS
IQV
Cancer Immunotherapy Research Report 2026: Market Forecasts 2025-2029 for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer with Executive and Consultant Guides
globenewswire.com
ABBV
ADAG
ADAP
ACET
ALXO
AMBR
AMGN
RCUS
AZN
ATRC
BBLU
BIIB
BNTX
BOLT
BMY
CRBU
CLDX
CRVS
LLY
EVAX
GNSS
GILD
GLSI
IMUX
IMMX
IMNM
INCY
INDP
ISRL
IOBT
JNJ
MRK
MRNA
MBIO
NVS
NVX
PDSB
PFE
REGN
SNY
SNT
URGN
ZYME
IO Biotech Provides Corporate Update
globenewswire.com
IOBT
IO Biotech Announces Exploration of Strategic Alternatives
globenewswire.com
IOBT
Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic
globenewswire.com
CAH
JNJ
PFE
IQV
IOBT
IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
globenewswire.com
IOBT